Invex Therapeutics Ltd has released a press release.
Invex and Peptron Mutually Terminate Manufacturing Agreement
Filed with ASX ·
6ix hasn’t read this filing yet.
Invex Therapeutics Ltd. on 6ix
Earlier from Invex Therapeutics
- Invex Granted European Patent for Exenatide in Hydrocephalus
- Proposed Capital Return to Shareholders of $14.0 Million
- Invex issued US patent for Traumatic Brain Injury
- Invex to close IIH Evolve Phase III Clinical Trial
- Phase III Clinical Trial Update and New IIH Market Analysis
Later from Invex Therapeutics
- Appendix 4D and Half year report
- ATO Class Ruling Return of Capital
- Invex receives R&D Tax Rebate
- Quarterly Activities Report and Appendix 4C
- Improved Neuronal Cell Survival in 3D Model of Alzheimer's
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics